Patents by Inventor Marian PERIS

Marian PERIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160304844
    Abstract: Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides.
    Type: Application
    Filed: July 1, 2016
    Publication date: October 20, 2016
    Inventors: Marian PERIS, Michael PHELAN, Barnett ROSENBLUM, Stephen HENDRICKS
  • Publication number: 20160265045
    Abstract: Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein.
    Type: Application
    Filed: June 1, 2016
    Publication date: September 15, 2016
    Inventors: Stephen P. HENDRICKS, Michael PHELAN, Marian PERIS, Cheng-Yao CHEN, Daniel MAZUR, Xinzhan PENG, Amy CASTILLO
  • Patent number: 9399767
    Abstract: Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: July 26, 2016
    Assignee: LIFT TECHNOLOGIES CORPORATION
    Inventors: Marian Peris, Michael Phelan, Barnett Rosenblum, Stephen Hendricks
  • Publication number: 20160208318
    Abstract: Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation.
    Type: Application
    Filed: January 8, 2016
    Publication date: July 21, 2016
    Inventors: Peter Vander Horn, Cheng-Yao Chen, Guobin Luo, Michael Previte, Jamshid Temirov, Theo Nikiforov, Zhaohui Zhou, Hongye Sun, Yufang Wang, Stefanie Yukiko Nishimura, Hongyi Wang, Marian Peris, Barnett Rosenblum, Michael Phelan
  • Publication number: 20160186224
    Abstract: In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of at least one agent that generates a ligatable terminal 5? phosphate group by removing an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, an aprataxin enzyme can catalyze removal of an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of an aprataxin enzyme under conditions suitable for ligating nucleic acid ends.
    Type: Application
    Filed: March 15, 2016
    Publication date: June 30, 2016
    Applicant: Life Technologies Corporation
    Inventors: Stephen Hendricks, David King, Lei Xi, Marian Peris
  • Patent number: 9365839
    Abstract: Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: June 14, 2016
    Assignee: Life Technologies Corporation
    Inventors: Stephen P. Hendricks, Michael Phelan, Marian Peris, Cheng-Yao Chen, Daniel Mazur, Xinzhan Peng, Amy Castillo
  • Patent number: 9315861
    Abstract: In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of at least one agent that generates a ligatable terminal 5? phosphate group by removing an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, an aprataxin enzyme can catalyze removal of an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of an aprataxin enzyme under conditions suitable for ligating nucleic acid ends.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: April 19, 2016
    Assignee: Life Technologies Corporation
    Inventors: Stephen Hendricks, David King, Lei Xi, Marian Peris
  • Patent number: 9255258
    Abstract: Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: February 9, 2016
    Assignee: Life Technologies Corporation
    Inventors: Peter Vander Horn, Cheng-Yao Chen, Guobin Luo, Michael Previte, Jamshid Temirov, Theo Nikiforov, Zhaohui Zhou, Hongye Sun, Yufang Wang, Stefanie Yukiko Nishimura, Hongyi Wang, Marian Peris, Barnett Rosenblum, Michael Phelan
  • Publication number: 20150247136
    Abstract: Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein.
    Type: Application
    Filed: May 12, 2015
    Publication date: September 3, 2015
    Inventors: Stephen P. HENDRICKS, Michael PHELAN, Marian PERIS, Cheng-Yao CHEN, Daniel MAZUR, Xinzhan PENG, Amy CASTILLO
  • Publication number: 20150031026
    Abstract: In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of at least one agent that generates a ligatable terminal 5? phosphate group by removing an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, an aprataxin enzyme can catalyze removal of an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of an aprataxin enzyme under conditions suitable for ligating nucleic acid ends.
    Type: Application
    Filed: November 28, 2012
    Publication date: January 29, 2015
    Inventors: Stephen Hendricks, David King, Lei Xi, Marian Peris
  • Publication number: 20140234940
    Abstract: Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides.
    Type: Application
    Filed: February 27, 2014
    Publication date: August 21, 2014
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Marian PERIS, Michael PHELAN, Barnett ROSENBLUM, Stephen HENDRICKS
  • Publication number: 20140234853
    Abstract: Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation.
    Type: Application
    Filed: December 16, 2013
    Publication date: August 21, 2014
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Peter VANDER HORN, Cheng-Yao CHEN, Guobin LUO, Michael PREVITE, Jamshid TEMIROV, Theo NIKIFOROV, Zhaohui ZHOU, Hongye SUN, Yufang WANG, Stefanie Yukiko NISHIMURA, Hongyi WANG, Marian PERIS, Barnett ROSENBLUM, Michael PHELAN
  • Patent number: 8703461
    Abstract: Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: April 22, 2014
    Assignee: Life Technologies Corporation
    Inventors: Marian Peris, Michael Phelan, Barnett Rosenblum, Stephen Hendricks
  • Patent number: 8632975
    Abstract: Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: January 21, 2014
    Assignee: Life Technologies Corporation
    Inventors: Peter B. Vander Horn, Cheng-Yao Chen, Guobin Luo, Michael Previte, Jamshid Temirov, Theo Nikiforov, Zhaohui Zhou, Hongye Sun, Yufang Wang, Stefanie Yukiko Nishimura, Hongyi Wang, Marian Peris, Barnett B. Rosenblum, Michael Phelan
  • Publication number: 20130005020
    Abstract: Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides.
    Type: Application
    Filed: August 31, 2012
    Publication date: January 3, 2013
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Marian PERIS, Michael PHELAN, Barnett B. ROSENBLUM, Stephen P. HENDRICKS
  • Publication number: 20120322057
    Abstract: Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein.
    Type: Application
    Filed: July 3, 2012
    Publication date: December 20, 2012
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Stephen P. HENDRICKS, Michael PHELAN, Marian PERIS, Cheng-Yao CHEN, Daniel MAZUR, Xinzhan PENG, Amy CASTILLO
  • Publication number: 20110159551
    Abstract: The present invention provides compositions and methods for a reverse transcription reaction using a reversibly inactivated reverse transcriptase enzyme. The reversibly inactivated reverse transcriptase enzyme results from a chemical modification which inactivates the reverse transcriptase enzyme. The activity of the reverse transcriptase enzyme is recovered by an incubation of the reaction mixture at elevated temperature prior to, or as part of the reverse transcription reaction. The reverse transcriptase enzyme of the present invention provides for a signficant reduction in non-specific reverse transcription from template nucleic acid molecules because the formulation of the reaction mixture does not support the formation of reverse transcription products prior to activation of the reverse transcriptase.
    Type: Application
    Filed: October 8, 2010
    Publication date: June 30, 2011
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Lei (a.k.a Larry) Xi, Roland Nagel, Stephen Hendricks, Jennifer Berkman, Marian Peris, Yulei Wang
  • Publication number: 20110014612
    Abstract: Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein.
    Type: Application
    Filed: March 26, 2010
    Publication date: January 20, 2011
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: STEPHEN P. HENDRICKS, MICHAEL PHELAN, MARIAN PERIS, CHENG-YAO CHEN, DANIEL MAZUR, XINZHAN PENG, AMY CASTILLO
  • Publication number: 20100330570
    Abstract: Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation.
    Type: Application
    Filed: May 28, 2010
    Publication date: December 30, 2010
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Peter B. VANDER HORN, Cheng-Yao Chen, Guobin Luo, Michael Previte, Jamshid Temirov, Theo Nikiforov, Zhaohui Zhou, Hongye Sun, Yufang Wang, Stefanie Yukiko Nishimura, Hongyi Wang, Marian Peris, Barnett B. Rosenblum, Michael Phelan
  • Publication number: 20100311144
    Abstract: Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides.
    Type: Application
    Filed: May 28, 2010
    Publication date: December 9, 2010
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Marian PERIS, Michael Phelan, Barnett B. Rosenblum, Stephen P. Hendricks